Sevelamer for Reducing Endotoxemia and Immune Activation
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
HIV-infected people can have an increase in inflammation in their body organs, even after
taking anti-HIV medicines.
Sevelamer carbonate is used to bind phosphate in dialysis patients. It can also bind
endotoxin in the gut and lowers endotoxin levels in the blood of dialysis patients. Sevelamer
carbonate decreases the inflammation endotoxin causes in dialysis patients.
A5296 is a phase II, single-arm study to evaluate the effect of 8 weeks of sevelamer
carbonate administration on markers of microbial translocation and T-cell activation in the
blood in chronically HIV-infected subjects not receiving ART.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)